Brevan Howard Capital Management LP Allogene Therapeutics, Inc. Transaction History
Brevan Howard Capital Management LP
- $14.2 Billion
- Q3 2024
A detailed history of Brevan Howard Capital Management LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 63,058 shares of ALLO stock, worth $122,963. This represents 0.0% of its overall portfolio holdings.
Number of Shares
63,058
Previous 59,705
5.62%
Holding current value
$122,963
Previous $139,000
26.62%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ALLO
# of Institutions
163Shares Held
134MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$36.5 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$32.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$16.2 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$13.7 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$13.4 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $280M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...